Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cipla
Healthtrust
AstraZeneca
Harvard Business School
Teva
Queensland Health
Accenture
Chinese Patent Office

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SPIRIVA RESPIMAT

« Back to Dashboard

Clinical Trials for Spiriva Respimat

Trial ID Title Status Sponsor Phase Summary
NCT00239447 Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD Completed Boehringer Ingelheim Phase 3 Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
NCT00281567 Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD) Completed Boehringer Ingelheim Phase 3 Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.
NCT00292448 A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed Boehringer Ingelheim Phase 2 The objective of this trial is to compare the efficacy and the safety of Ba 679 BR Respimat 5 ug once daily to tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule) in a crossover study of 4-week treatment periods in patients with COPD.
NCT00981851 Interaction in Chronic Obstructive Pulmonary Disease Experiment Completed Radboud University N/A The final purpose of this study is to determine whether bronchodilation and cigarette smoking in Chronic Obstructive Pulmonary Disease (COPD) patients interact, resulting in an increase of cardiovascular disease. The aim of this part of the study is to demonstrate the basic mechanism: Does increased respiratory function after administration of a bronchodilator in patients with COPD lead to elevated pulmonary retention of the harmful compounds in inhaled cigarette smoke and to short-term biological effects associated with cardiovascular disease?
NCT01179347 Tiotropium Bromide in Cystic Fibrosis Completed Boehringer Ingelheim Phase 3 To date, there have been no formal clinical studies completed using tiotropium in CF patients. While there is a large body of evidence demonstrating the efficacy and safety of tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD), relatively little is known about its efficacy and safety in patients with a diagnosis of cystic fibrosis. Therefore, Boehringer Ingelheim proposed to profile the long acting anticholinergic tiotropium and to generate adequate clinical data for use as a bronchodilator in paediatric and adult CF. The phase III trial (205.438) is a part of the approved Paediatric Investigation Plan (PIP) agreed for Spiriva® Respimat® in Cystic Fibrosis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Spiriva Respimat

Condition Name

Condition Name for Spiriva Respimat
Intervention Trials
Pulmonary Disease, Chronic Obstructive 6
Healthy 4
Asthma 3
COPD 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Spiriva Respimat
Intervention Trials
Pulmonary Disease, Chronic Obstructive 11
Lung Diseases 9
Chronic Disease 6
Lung Diseases, Obstructive 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Spiriva Respimat

Trials by Country

Trials by Country for Spiriva Respimat
Location Trials
United States 135
Canada 6
United Kingdom 5
Australia 3
Germany 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Spiriva Respimat
Location Trials
South Carolina 6
California 6
North Carolina 5
Ohio 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Spiriva Respimat

Clinical Trial Phase

Clinical Trial Phase for Spiriva Respimat
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2/Phase 3 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Spiriva Respimat
Clinical Trial Phase Trials
Completed 13
Recruiting 4
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Spiriva Respimat

Sponsor Name

Sponsor Name for Spiriva Respimat
Sponsor Trials
Boehringer Ingelheim 8
3M 4
Pearl Therapeutics, Inc. 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Spiriva Respimat
Sponsor Trials
Industry 19
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Cerilliant
US Army
Chinese Patent Office
US Department of Justice
Queensland Health
Cipla
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.